The selective GSK3β inhibitor lithium has been reported to promote the motility of colon cancer cells [33], whereas treating cultured cells with GSK3 inhibitors or small interfering RNA (siRNA) targeting GSK3 has been reported to inhibit motility [34]. Here, GSK3B is linked to colonic neoplasm.